SMARCA4 and neoplasm: A strategy that would allow for the efficient Brg1 deletion in existing adenomas or the use of a Brg1 inhibitor would be required to further address the effects of Brg1 in non-stem cell portion of established Wnt-driven tumours, as well as the potential therapeutic window of targeting Brg1.